ANGPTL4
ANGPTL4 (Angiopoietin-like 4) is a protein that in humans is encoded by the ANGPTL4 gene. This protein is a member of the angiopoietin-like family of secreted factors. It is involved in various processes such as lipid metabolism, glucose homeostasis, inflammation, and wound healing. The protein has been identified as playing a role in the regulation of lipoprotein lipase (LPL) activity among other functions. Variants and expression levels of ANGPTL4 have been linked to metabolic conditions such as obesity, insulin resistance, and cardiovascular diseases.
Function[edit | edit source]
ANGPTL4 is involved in the regulation of lipid metabolism by inhibiting the activity of lipoprotein lipase (LPL), an enzyme that hydrolyzes triglycerides in lipoproteins, releasing free fatty acids for uptake by tissues. This inhibition is crucial for the modulation of plasma triglyceride levels. Additionally, ANGPTL4 is implicated in glucose homeostasis and insulin sensitivity, and it has been shown to have anti-inflammatory and wound healing properties. Its role in these processes makes it a potential therapeutic target for treating metabolic diseases.
Genetics[edit | edit source]
The ANGPTL4 gene is located on chromosome 19p13.11 and consists of several exons and introns. Variations in this gene have been associated with differences in lipid and glucose metabolism among individuals. Some polymorphisms in the ANGPTL4 gene have been linked to an increased risk of developing metabolic syndromes, such as type 2 diabetes and cardiovascular diseases.
Clinical Significance[edit | edit source]
Research has indicated that ANGPTL4 may play a significant role in the pathogenesis of various metabolic disorders. Elevated levels of ANGPTL4 have been observed in conditions such as obesity, insulin resistance, and type 2 diabetes, suggesting its involvement in the development of these diseases. Furthermore, ANGPTL4 has been studied for its potential as a biomarker for cardiovascular risk and its therapeutic implications in treating metabolic diseases through the modulation of lipid and glucose metabolism.
Potential Therapeutic Target[edit | edit source]
Given its central role in lipid and glucose metabolism, ANGPTL4 presents a promising target for the development of drugs aimed at treating metabolic disorders. Inhibitors of ANGPTL4 could potentially be used to lower plasma triglyceride levels, improve insulin sensitivity, and reduce the risk of cardiovascular diseases. Ongoing research is focused on understanding the precise mechanisms by which ANGPTL4 influences metabolism and how it can be targeted therapeutically.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD